Takeda Pharmaceutical
| Takeda Pharmaceutical Company Limited | |
|---|---|
| Type | Public |
| Traded as | TYO: 4502 NYSE: TAK Nikkei 225 component |
| Industry | Pharmaceuticals |
| Founded | 12 June 1781, Osaka, Japan |
| Founder | Chobei Takeda I |
| Headquarters | Nihonbashi, Tokyo, Japan; global operations centre in Cambridge, Massachusetts |
| Key people | Christophe Weber (President and chief executive officer) |
| Products | Oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies, vaccines |
| Employees | Approximately 49,000 |
| Website | takeda.com |
Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company headquartered in Tokyo, with a global operations centre in Cambridge, Massachusetts. It is the largest pharmaceutical company in Japan and Asia and among the fifteen largest in the world.
The company traces its founding to 12 June 1781, when Chobei Takeda I began selling traditional Japanese and Chinese medicines in Doshomachi, the pharmaceutical district of Osaka. It is therefore among the oldest pharmaceutical companies in existence and considerably older than most of its competitors.
Its modern form dates from the acquisition of the Irish-domiciled Shire in January 2019 for approximately US$62 billion, the largest overseas acquisition ever conducted by a Japanese company. The transaction transformed Takeda from a regional company with a domestic orientation into a global one, and it also burdened it with very large debt that has determined its conduct since.
Takeda concentrates on oncology, rare genetic and haematological diseases, neuroscience, gastroenterology and plasma-derived therapies, together with vaccines. Its largest product is Entyvio, a treatment for inflammatory bowel disease.
History
The Osaka merchant, 1781 to 1945
Chobei Takeda I established the business in Doshomachi, the district in Osaka where the wholesale medicine trade had been concentrated since the seventeenth century under a licensing system established by the shogunate.
The business dealt in traditional Japanese and Chinese preparations for its first century. The transformation came with the Meiji Restoration and the adoption of Western medicine: Takeda began importing European pharmaceuticals in 1871, established its own manufacturing in 1895, and began research in 1915.
The company was incorporated in 1925 as Chobei Takeda and Company and renamed Takeda Pharmaceutical Industries in 1943.
Its early research produced vitamin preparations, and Alinamin, a vitamin B1 derivative introduced in 1954 and marketed for fatigue, became among the best-known consumer health products in Japan and remained so for decades.
Post-war expansion, 1945 to 2000
Takeda grew with the Japanese economy and with the establishment of universal health insurance in 1961, which created a very large domestic market.
Its research produced a sequence of commercially significant medicines, of which the most important were Blopress (candesartan) for hypertension, Prevacid (lansoprazole), a proton pump inhibitor for acid-related disease introduced in 1992, and Actos (pioglitazone), a treatment for type 2 diabetes launched in 1999.
The company's international strategy for most of this period was to license its discoveries to Western companies rather than to build its own commercial organisation, principally through arrangements with Abbott for Prevacid and with Eli Lilly for Actos. This produced revenue without risk and left Takeda without the international infrastructure that would later be required.
Internationalisation, 2000 to 2018
The problem that drove everything since became apparent in the 2000s: the patents on Blopress, Prevacid and Actos would expire within a few years of each other, Takeda's pipeline could not replace them, and the company had no meaningful presence outside Japan.
Its response was acquisition. Syrrx and Paradigm were bought in 2005, Millennium Pharmaceuticals of Cambridge, Massachusetts in 2008 for approximately US$8.8 billion, bringing Velcade for multiple myeloma and an American research base, and Nycomed of Switzerland in 2011 for approximately €9.6 billion, bringing European and emerging market commercial operations.
Christophe Weber, a French executive from GSK, was appointed in 2014, becoming the first non-Japanese chief executive of the company and one of very few to lead a major Japanese corporation. The appointment was contested internally, with a group of former executives and descendants of the founding family publicly opposing it on the ground that a foreign chief executive would not preserve the company's character, and the dispute was reported extensively in Japan.
Weber moved the company's research to Boston, made English the working language, reduced Japanese employment and reoriented the portfolio.
Shire, 2018 to 2026
Shire was an Irish-domiciled company with origins in the United Kingdom, specialising in rare diseases, haematology and attention deficit hyperactivity disorder, whose own growth had been by acquisition and which had absorbed Baxalta, the plasma and haematology business spun out of Baxter, in 2016.
Takeda agreed to acquire it in May 2018 for approximately US$62 billion in cash and shares, completing on 8 January 2019.
The transaction was the largest ever conducted by a Japanese company abroad and it was contested. The same group of former executives and founding family descendants campaigned against it, arguing that the debt was excessive and that the company was being transformed into something unrecognisable, and it required a shareholder vote that passed with approximately 88 per cent support.
The strategic case was that Shire's rare disease portfolio was protected by the difficulty of manufacturing biologics and plasma products rather than by patents alone, that its products had long lives, and that the combination would produce sufficient scale to fund research.
The financial case was more difficult. Takeda borrowed approximately US$30 billion, took its debt to several times earnings, and committed to a programme of divestments, of which more than US$10 billion of non-core products were sold within two years, and to reducing leverage, which has occupied the company since.
Recent developments include approval in February 2024 for Eohilia, the first oral treatment approved in the United States for eosinophilic oesophagitis, an allergic inflammation of the oesophagus, for patients aged eleven and over; the announcement in May 2024 of 641 redundancies in Massachusetts, affecting Cambridge and Lexington; an agreement in October 2025 with China's Innovent Biologics valued at approximately US$11.4 billion covering immuno-oncology and antibody-drug conjugate development; and an announcement in May 2026 of approximately 4,500 redundancies across global operations.
Products
Entyvio (vedolizumab), a monoclonal antibody for ulcerative colitis and Crohn's disease, is the company's largest product. It acts selectively on the gut, which produces a better safety profile than systemic immunosuppression, and a subcutaneous version approved in 2023 extended its life.
Takhzyro (lanadelumab) prevents attacks of hereditary angioedema, a rare genetic condition causing severe swelling.
Vyvanse (lisdexamfetamine), from Shire, treats attention deficit hyperactivity disorder and lost American exclusivity in 2023, producing a very large revenue decline.
Plasma-derived therapies, from the Baxalta business, include immunoglobulins and clotting factors, and are unusual in that they are made from donated human plasma rather than synthesised, which means that supply is limited by donation and that the manufacturing is difficult to replicate.
Oncology includes Alunbrig, Adcetris in partnership, Iclusig and Ninlaro.
Neuroscience includes Trintellix, and the company has an orexin programme for narcolepsy which is among the more closely watched in its pipeline.
Vaccines include Qdenga, a dengue vaccine approved in the European Union, Indonesia, Brazil and elsewhere from 2022, which addresses a disease affecting a very large number of people and for which the previous vaccine had serious limitations. Takeda has committed to producing a very large number of doses and has partnered with Biological E in India for manufacturing.
Business and strategy
Takeda's revenue is approximately ¥4.5 trillion, with the United States the largest market, followed by Japan, Europe and emerging markets.
Its strategic problem is straightforward. The Shire acquisition brought products and debt in roughly equal measure, several of the acquired products have lost or will lose exclusivity, and the pipeline must produce replacements before the losses accumulate.
The company has responded by concentrating research on a small number of areas, by partnering extensively rather than developing alone, of which the Innovent agreement is the largest example, by divesting non-core products and by reducing costs, of which the 2024 and 2026 redundancy programmes are the visible part.
Its research is conducted principally in Boston, in Japan and in San Diego, and it has an unusually extensive programme of external partnerships and of investments in small biotechnology companies, on the reasoning that a company of its size cannot discover enough internally.
Corporate affairs
Christophe Weber has been chief executive since 2014 and president since 2015. His tenure has been the most consequential in the company's modern history and the most contested, involving the first foreign leadership, the move of research to the United States, the change of working language and the Shire transaction.
The company is headquartered at Nihonbashi in Tokyo, close to Doshomachi's successor district, with its global operations centre in Cambridge, Massachusetts, and substantial sites in Osaka, Singapore, Vienna, Zurich, Dublin and Germany, where it operates plants at Konstanz, Berlin, Singen and Oranienburg, the German business having been established at Aachen in 1981 and directed from Berlin since 2012.
Takeda employs approximately 49,000 people and is listed in Tokyo and, through American depositary shares, in New York.
Criticism
Actos. Takeda faced very large litigation in the United States over pioglitazone and bladder cancer risk, including a 2014 jury award of US$9 billion in punitive damages, reduced by the judge to approximately US$37 million, and a settlement of approximately US$2.4 billion in 2015 covering thousands of claims. The allegations included that the company had destroyed documents relevant to the litigation, for which sanctions were imposed.
Shire's debt. The scale of borrowing required and the divestments that followed have been criticised, principally by the group of former executives who opposed the transaction, as having compromised the company's research capacity for a portfolio whose durability was overstated.
Japanese identity. The transformation of a company founded in 1781 into an internationally managed business operating in English, with its research abroad and its leadership foreign, has been a subject of substantial domestic argument, and the opposition has been conducted in terms that are as much cultural as financial.
Pricing of rare disease products, which is very high per patient because the populations are small, attracts the criticism that applies to the category generally.
Assessment
Takeda is a company that solved a genuine problem in a way that created a different one.
The problem was that a Japanese pharmaceutical company dependent on a domestic market with a shrinking and ageing population, with patent expiries approaching on its three principal products and without an international commercial organisation, had no future as an independent business. Every large Japanese pharmaceutical company faced the same position and most responded less decisively.
The solution was to become international by purchase, which required paying US$62 billion for Shire and borrowing US$30 billion to do it, and to accept a degree of transformation, foreign leadership, English as the working language, research relocated to Boston, that no comparable Japanese company has accepted.
The result is a global company in the second rank of the industry, with a genuinely differentiated position in rare disease and plasma therapies, carrying more debt than its peers and facing exclusivity losses that its pipeline has not yet demonstrated it can replace.
Whether the transformation succeeds will be determined by the pipeline rather than by the strategy, which is true of every pharmaceutical company and which is the reason the industry's outcomes are less predictable than its plans.